A Randomized Trial of Nafamostat for Covid-19
A Randomized Trial of Nafamostat for Covid-19Nafamostat mesylate is a potent in vitro antiviral that inhibits the host transmembrane protease serine 2 enzyme used by SARS-CoV-2 for cell entry. Morpeth et al report the results of an open-label randomized clinical trial of nafamostat for noncritically ill patients with Covid-19.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
---|---|
Enthalten in: |
NEJM evidence - 2(2023), 11 vom: 05. Nov., Seite EVIDoa2300132 |
Sprache: |
Englisch |
---|
Links: |
---|
Themen: |
Benzamidines |
---|
Anmerkungen: |
Date Completed 08.02.2024 Date Revised 08.02.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1056/EVIDoa2300132 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368099040 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368099040 | ||
003 | DE-627 | ||
005 | 20240208232113.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240207s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1056/EVIDoa2300132 |2 doi | |
028 | 5 | 2 | |a pubmed24n1284.xml |
035 | |a (DE-627)NLM368099040 | ||
035 | |a (NLM)38320527 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Morpeth, Susan C |e verfasserin |4 aut | |
245 | 1 | 2 | |a A Randomized Trial of Nafamostat for Covid-19 |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 08.02.2024 | ||
500 | |a Date Revised 08.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a A Randomized Trial of Nafamostat for Covid-19Nafamostat mesylate is a potent in vitro antiviral that inhibits the host transmembrane protease serine 2 enzyme used by SARS-CoV-2 for cell entry. Morpeth et al report the results of an open-label randomized clinical trial of nafamostat for noncritically ill patients with Covid-19 | ||
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Journal Article | |
650 | 7 | |a nafamostat |2 NLM | |
650 | 7 | |a Y25LQ0H97D |2 NLM | |
650 | 7 | |a Guanidines |2 NLM | |
650 | 7 | |a Benzamidines |2 NLM | |
700 | 1 | |a Venkatesh, Balasubramanian |e verfasserin |4 aut | |
700 | 1 | |a Totterdell, James A |e verfasserin |4 aut | |
700 | 1 | |a McPhee, Grace M |e verfasserin |4 aut | |
700 | 1 | |a Mahar, Robert K |e verfasserin |4 aut | |
700 | 1 | |a Jones, Mark |e verfasserin |4 aut | |
700 | 1 | |a Bandara, Methma |e verfasserin |4 aut | |
700 | 1 | |a Barina, Lauren A |e verfasserin |4 aut | |
700 | 1 | |a Basnet, Bhupendra K |e verfasserin |4 aut | |
700 | 1 | |a Bowen, Asha C |e verfasserin |4 aut | |
700 | 1 | |a Burke, Andrew J |e verfasserin |4 aut | |
700 | 1 | |a Cochrane, Belinda |e verfasserin |4 aut | |
700 | 1 | |a Denholm, Justin T |e verfasserin |4 aut | |
700 | 1 | |a Dhungana, Ashesh |e verfasserin |4 aut | |
700 | 1 | |a Dore, Gregory J |e verfasserin |4 aut | |
700 | 1 | |a Dotel, Ravindra |e verfasserin |4 aut | |
700 | 1 | |a Duffy, Eamon |e verfasserin |4 aut | |
700 | 1 | |a Dummer, Jack |e verfasserin |4 aut | |
700 | 1 | |a Foo, Hong |e verfasserin |4 aut | |
700 | 1 | |a Gilbey, Timothy L |e verfasserin |4 aut | |
700 | 1 | |a Hammond, Naomi E |e verfasserin |4 aut | |
700 | 1 | |a Hudson, Bernard J |e verfasserin |4 aut | |
700 | 1 | |a Jha, Vivekanand |e verfasserin |4 aut | |
700 | 1 | |a Jevaji, Purnima R |e verfasserin |4 aut | |
700 | 1 | |a John, Oommen |e verfasserin |4 aut | |
700 | 1 | |a Joshi, Rajesh |e verfasserin |4 aut | |
700 | 1 | |a Kang, Gagandeep |e verfasserin |4 aut | |
700 | 1 | |a Kaur, Baldeep |e verfasserin |4 aut | |
700 | 1 | |a Kim, Seungtaek |e verfasserin |4 aut | |
700 | 1 | |a Das, Santa Kumar |e verfasserin |4 aut | |
700 | 1 | |a Lau, Jillian S Y |e verfasserin |4 aut | |
700 | 1 | |a Littleford, Roberta |e verfasserin |4 aut | |
700 | 1 | |a Marsh, Julie A |e verfasserin |4 aut | |
700 | 1 | |a Marschner, Ian C |e verfasserin |4 aut | |
700 | 1 | |a Matthews, Gail |e verfasserin |4 aut | |
700 | 1 | |a Maze, Michael J |e verfasserin |4 aut | |
700 | 1 | |a McArthur, Colin J |e verfasserin |4 aut | |
700 | 1 | |a McFadyen, James D |e verfasserin |4 aut | |
700 | 1 | |a McMahon, James H |e verfasserin |4 aut | |
700 | 1 | |a McQuilten, Zoe K |e verfasserin |4 aut | |
700 | 1 | |a Molton, James |e verfasserin |4 aut | |
700 | 1 | |a Mora, Jocelyn M |e verfasserin |4 aut | |
700 | 1 | |a Mudaliar, Vijaybabu |e verfasserin |4 aut | |
700 | 1 | |a Nguyen, Vi |e verfasserin |4 aut | |
700 | 1 | |a O'Sullivan, Matthew V N |e verfasserin |4 aut | |
700 | 1 | |a Pant, Suman |e verfasserin |4 aut | |
700 | 1 | |a Park, Jaha E |e verfasserin |4 aut | |
700 | 1 | |a Paterson, David L |e verfasserin |4 aut | |
700 | 1 | |a Price, David J |e verfasserin |4 aut | |
700 | 1 | |a Raymond, Nigel |e verfasserin |4 aut | |
700 | 1 | |a Rees, Megan A |e verfasserin |4 aut | |
700 | 1 | |a Robinson, James O |e verfasserin |4 aut | |
700 | 1 | |a Rogers, Benjamin A |e verfasserin |4 aut | |
700 | 1 | |a Ryu, Wang-Shick |e verfasserin |4 aut | |
700 | 1 | |a Sasadeusz, Joe |e verfasserin |4 aut | |
700 | 1 | |a Shum, Omar |e verfasserin |4 aut | |
700 | 1 | |a Snelling, Thomas L |e verfasserin |4 aut | |
700 | 1 | |a Sommerville, Christine |e verfasserin |4 aut | |
700 | 1 | |a Trask, Nanette |e verfasserin |4 aut | |
700 | 1 | |a Lewin, Sharon R |e verfasserin |4 aut | |
700 | 1 | |a Hills, Thomas E |e verfasserin |4 aut | |
700 | 1 | |a Davis, Joshua S |e verfasserin |4 aut | |
700 | 1 | |a Roberts, Jason A |e verfasserin |4 aut | |
700 | 1 | |a Tong, Steven Y C |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t NEJM evidence |d 2022 |g 2(2023), 11 vom: 05. Nov., Seite EVIDoa2300132 |w (DE-627)NLM339641495 |x 2766-5526 |7 nnns |
773 | 1 | 8 | |g volume:2 |g year:2023 |g number:11 |g day:05 |g month:11 |g pages:EVIDoa2300132 |
856 | 4 | 0 | |u http://dx.doi.org/10.1056/EVIDoa2300132 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 2 |j 2023 |e 11 |b 05 |c 11 |h EVIDoa2300132 |